- Report
- October 2024
- 183 Pages
Global
From €3181EUR$3,545USD£2,738GBP
€3534EUR$3,939USD£3,042GBP
- Report
- February 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- February 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- May 2024
- 137 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- March 2024
- 200 Pages
Global
From €3724EUR$4,150USD£3,205GBP
- Report
- April 2023
- 110 Pages
Global
From €4262EUR$4,750USD£3,668GBP
- Report
- January 2024
- 107 Pages
Global
From €3500EUR$4,178USD£3,118GBP
- Report
- April 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,047GBP
Gemfibrozil is a lipid-lowering medication used to treat high cholesterol and triglyceride levels in the blood. It is a member of the fibrate class of drugs, which are used to reduce the risk of cardiovascular disease. Gemfibrozil works by increasing the breakdown of triglycerides in the liver, reducing the amount of fat in the blood. It also increases the production of HDL (good) cholesterol, which helps to reduce the risk of heart disease. Gemfibrozil is often prescribed in combination with other cholesterol-lowering medications, such as statins.
The market for Gemfibrozil is highly competitive, with many pharmaceutical companies offering their own versions of the drug. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Other companies, such as Mylan and Teva, also offer generic versions of the drug. Show Less Read more